<DOC>
	<DOCNO>NCT02116582</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety enzalutamide treatment patient progressive metastatic castration-resistant prostate cancer previously treat abiraterone acetate .</brief_summary>
	<brief_title>A Study Evaluate Enzalutamide After Abiraterone Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subject histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature . Subject metastatic disease document bone scan soft tissue disease observe Computed Tomography/Magnetic Resonance Imaging ( CT/MRI ) screening , within ≤30 day prior Day 1 . In set castrate level testosterone ≤1.7 nmol/L ( ≤50 ng/dL ) , subject progressive disease study entry define PSA rise determine minimum 2 rise PSA level interval ≥ 1 week assessment . The PSA value screen visit ≥ 2 ng/mL WITH WITHOUT : Soft tissue disease progression define Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 ) screening , within ≤30 day prior Day 1 . Measurable disease require entry . Lymph nod ≥ 2 cm consider measurable disease ( Prostate Cancer Clinical Trials Working Group ( PCWG2 ) ) . Bone disease progression define least 2 new lesion bone scan screening , within ≤30 day prior Day 1 . Subject must receive minimum 24 week treatment abiraterone acetate within approve label indication discontinue use least 4 week prior start study drug Day 1 . If subject receive previous treatment chemotherapy prostate cancer , must limit one prior line docetaxel , must use prior abiraterone acetate therapy . Subject receives continue receive ongoing androgen deprivation Luteinizinghormonereleasing hormone ( LHRH ) analogue therapy throughout course study bilateral orchiectomy . Subject asymptomatic mildly symptomatic prostate cancer : The score Brief Pain Inventory Short Form ( BPISF ) Question # 3 must &lt; 4 . No use opiate analgesic prostate cancerrelated pain currently anytime within 4 week prior screen . Subject prior use ketoconazole treatment prostate cancer . Subject prior use cabazitaxel . Subject prior use enzalutamide . Subject receive ANY antineoplastic therapy ( include antiandrogens chemotherapy ) follow abiraterone acetate discontinuation prior start study drug Day 1 . Subject know suspected hypersensitivity enzalutamide , component formulation use . Subject know suspected brain metastasis active leptomeningeal disease . Subject history seizure condition may predispose seizure ( e.g. , prior stroke significant brain trauma ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>Xtandi</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Metastatic Castration-Resistant Prostate Cancer</keyword>
	<keyword>Enzalutamide</keyword>
</DOC>